Pharma, Biotech and Generics Industry News | The Pharmaletter
Pharmaceutical. 30 September 2024 India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. Generics. 30 September 2024 The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related ...
About The Pharma Letter | The Pharmaletter
The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.
Pharmaceutical Industry News | The Pharmaletter
Sep 27, 2024 · F2G seeks second bite of the cherry with $100 million round as novel antifungal pipeline remains thin. F2G’s September $100m funding round provides the company with crucial funds to renavigate approval of its lead drug, olorofim. The substantial financing also highlights the paucity of novel antifungal products in the clinic. 3 October 2024.
Pharma M&A news | The Pharmaletter
Sep 19, 2024 · Fosun Pharma secures full ownership of Fosun Kite with $27 million deal. Shanghai-based Fosun Pharmaceutical has announced it has acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 million, giving it full control of the joint venture. 23 September 2024. Pharmaceutical.
BeiGene sues Sandoz and MSN for Brukinsa patent infringement
9 March 2024. Sino-American biotech BeiGene (Nasdaq: BGNE) on March 8 disclosed in stock exchange announcement that it has filed patent infringement suits under the Hatch-Waxman Act against the US subsidiary of Swiss firm Sandoz (SIX: SDZ) and separately against Indian-owned companies MSN Pharmaceuticals and MSN Laboratories Private in the US ...
Pharma News and Insights Podcast | The Pharmaletter
Jul 17, 2023 · The Pharma Letter Podcast — Episode 25 — The need for change for major depressive disorder patients. Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism.10 October 2023.
Login - The Pharmaletter
5 days ago · The Pharma Letter. 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom
Axon Pharma | | The Pharmaletter | The Pharmaletter
Axon Pharma. "A dynamic and versatile pharmaceutical company with regional horizons in Latin America." "Axon Pharma is an independent multinational pharmaceutical company built on high-standards science and management. Today, Axon Pharma is one of the fastest growing companies with proven track record in CNS and OTC segments.
Hodgkin's lymphoma market to suffer with Adcetris patent expiry, …
Aug 19, 2020 · Adcetris (brentuximab vedotin) is the market-leading drug in the world’s 7MM (the USA, France, Germany, Italy, Spain, the UK and Japan) markets and the main contributor to the market growth in Hodgkin’s lymphoma (HL) over the recent years. Adcetris is being jointly developed and marketed by Japanese drugmaker Takeda (TYO: 4502) and US ...
Teijin Pharma grants exclusive license to Bioprojet
Apr 10, 2024 · Under the terms of the agreement, Teijin Pharma grants Bioprojet exclusive worldwide rights to research, develop, manufacture and commercialize an investigational candidate for narcolepsy. Shares of the parent company closed up 3.8% at 1,500 yen following the announcement. The investigational candidate is a highly potent and selective orexin 2 ...